Lilly Reports 55% ORR with Next-Generation FRα-Targeting ADC LY4170156 in Phase 1 Trial for Platinum-Resistant Ovarian Cancer

At the 2025 ASCO Annual Meeting, Eli Lilly and Company presented its FRα-targeted ADC LY4170156.Treatment of Platinum-Resistant Ovarian CancerThe first-in-human clinical trial data. This Phase Ⅰ data shows that, at the Phase Ⅱ recommended dose of 4 mg/kg, preliminary observations indicateOverall Objective Response Rate (ORR)55%。

Screenshot source: Eli Lilly and Company official website

LY4170156 is a folate receptor α-targeted agent (FRα) The next-generation ADC under research. FRα is a cell surface glycoprotein encoded by the FOLR1 gene and is overexpressed in many solid tumors, such as ovarian cancer, non-small cell lung cancer, and colorectal cancer.

This publication presents the first-in-human Phase I study data of LY4170156. As of the data cutoff date of March 9, 2025, the study enrolled a total of 95 patients with high-grade serous ovarian cancer across four dose levels.（2-6 mg/kg）The median number of previous systemic treatment regimens received by the patients was 5, with 15% of the patients having previously received mirvetuximab soravtansine.

Among 95 patients, 51% had tumor FRα expression below 75%, 34% had FRα expression at or above 75%, and 16% had pending expression results. The key endpoints of the study were safety, pharmacokinetics, and anti-tumor activity (per RECIST v1.1 criteria).

Efficacy results showed that all patients at all dose levels and all FRα expression levels, including those who had progressed after prior treatment with mirvetuximab soravtansine, experienced relief. Among 58 evaluable patients,ORR was 45%(26/58 cases)，The disease control rate was 74%.(43/58 cases)。At the potential recommended Phase II dose of 4 mg/kg, the ORR was 55%.(11/20 cases)。

The most common treatment-emergent adverse events across all dose levels included nausea, anemia, fatigue, vomiting, diarrhea, and neutropenia. To date, no treatment-emergent neuropathy or ocular toxicity has been observed. The maximum tolerated dose has not been determined.

In summary, the study concluded that LY4170156 demonstrated encouraging safety and antitumor activity across different doses and levels of FRα expression in heavily pretreated women with platinum-resistant ovarian cancer.

Screenshot source: Insight database

The 2025 ASCO Conference is currently underway. To learn more about the research data disclosed at this year's ASCO, you can scan the QR code below for access. Insight Database "Clinical Trial Results Module"To view.

Cover Source:Insight Database Chart

Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If needed, please consult and contact正规医疗机构.

Editor: Xinyao

PR Article Coordination: WeChat insightxb